November 7, 2011 David Lawrence Warwick, NY 10990 Re: Amendment to Employment Agreement Dear David:Acorda Therapeutics Inc • February 28th, 2012 • Biological products, (no disgnostic substances)
This letter serves as an amendment to your employment letter agreement, dated December 19, 2005, with Acorda Therapeutics, Inc., as previously amended (the “Agreement”), in accordance with paragraph 8(b) of the Agreement. Specifically, the Agreement is amended as follows, effective as of the date written above:
October 19, 2011 Enrique Carrazana, M.D. White Plains, NY 10601 Dear Dr. Carrazana:Acorda Therapeutics Inc • February 28th, 2012 • Biological products, (no disgnostic substances) • New York
We are delighted to present this letter agreement (the “Agreement”), setting out certain severance benefits available to you in the event of a change in control of Acorda Therapeutics, Inc. (the “Company”). If these terms are acceptable, please sign the copy of this letter provided herewith and return it to me at your first convenience. If you accept the terms offered herein, this Agreement shall be deemed to be effective as of the date written above (the “Effective Date”).
CONSULTING AGREEMENTConsulting Agreement • February 28th, 2012 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Consulting Agreement (this "Agreement") is entered into by and between Acorda Therapeutics, Inc., a Delaware corporation, with offices at 15 Skyline Drive, Hawthorne, NY 10532 (the "Company") of Thomas C. Wessel, M.D., Ph.D., residing at 22 Cliffwood Street, Lenox, MA 01240 ("Consultant") as a consultant to the Company. This Agreement shall be effective as of October 1, 2011 (“Effective Date”).
November 7, 2011 Jane Wasman New York, NY 10023 Re: Amendment to Employment Agreement Dear Jane:Acorda Therapeutics Inc • February 28th, 2012 • Biological products, (no disgnostic substances)
This letter serves as an amendment to your employment letter agreement, dated December 19, 2005, with Acorda Therapeutics, Inc., as previously amended (the “Agreement”), in accordance with paragraph 8(b) of the Agreement. Specifically, the Agreement is amended as follows, effective as of the date written above:
November 7, 2011 Dr. Thomas C. Wessel Lenox, MA 01240 RE: SEPARATION AGREEMENT AND GENERAL RELEASE Dear Tom:Acorda Therapeutics Inc • February 28th, 2012 • Biological products, (no disgnostic substances) • New York
This letter (the “Agreement”) confirms that your employment with Acorda Therapeutics, Inc. (the "Company") terminated effective the close of business September 30, 2011. You have no further job responsibilities with the Company as an employee thereof. However, pursuant to a Consulting Agreement effective as of October 1, 2011, between you and the Company (the “Consulting Agreement”), you are continuing to provide consulting services to the Company for the “Term,” and subject to the terms and conditions, specified therein. For purposes of this Agreement, the “Final Service Date” means the last day of the Term of the Consulting Agreement.
